Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
about
Clinical outcome measures in juvenile idiopathic arthritisThe Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative ReviewEfficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trialsTreatment of juvenile idiopathic arthritis: a revolution in careReview: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?Targeting interleukin-1 in heart diseaseAdvances in the genetically complex autoinflammatory diseasesNeutralizing anti-interleukin-1β antibodies modulate fetal blood-brain barrier function after ischemia.IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentAdult-onset Still's disease: current challenges and future prospectsEvasion of inflammasome activation by microbial pathogensBiomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromesJuvenile Idiopathic Arthritis in the Era of International Cooperation.Macrophage Activation Syndrome.Juvenile Idiopathic Arthritis2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aBlood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studiesPotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges.Treatment of adult-onset Still's disease: a reviewIL-1 blockade in autoinflammatory syndromes.Polyarticular juvenile idiopathic arthritis - epidemiology and management approachesThe molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.Indications for IVIG in rheumatic diseasesTolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.The development and assessment of biological treatments for children.Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.An expanding role for interleukin-1 blockade from gout to cancer.IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases.Targeting the inflammasome in rheumatic diseases.Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverBiological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
P2860
Q26752701-E55DDAD4-3218-47D7-BB81-46A593919BFBQ26768281-A3610B91-CC65-46D2-9360-D9A6761241FAQ26775512-E24FE99D-F422-480B-80EF-02BB36338CD7Q26849497-1B627969-BFA5-413A-B459-524A53990E42Q27002805-08930ECA-CE05-4D3C-A695-26D8D8D6C713Q27009347-18FD0A31-C013-44D5-BD17-6592F4909BBCQ27025795-75072B2A-C814-4F41-99EB-C28156D99A5AQ27308341-2701B532-D778-4947-A5EE-C4958FEA8FD3Q28078134-AAB5F8AC-B8BB-4039-8774-5171C2BCA426Q28079246-D2BB699C-07A5-420A-AA29-6DF9EEB84882Q28079446-82DF11F3-1A2B-40E8-A9B4-757052346889Q28082757-6F18DA0E-2F0F-4D2A-A291-8C372E024D4AQ28647737-9A44C7DB-724B-445A-81EC-656B21FF9F1EQ30235998-42DCBFC0-63DD-494C-A7DD-DD0B35226382Q33426151-EABFC751-D566-4A3B-A523-1D420AAFB2E3Q33572045-208AC75E-0488-4005-ADD1-AA7F9E468978Q33613293-258195C5-9C35-4B0E-A9B5-E709A9350603Q33622723-DAEBD341-E9E1-4D8F-A376-1FE3FC695E25Q33661359-E79F706C-8589-47B1-B20D-CA233A4ECE9CQ33710807-3E4AE1EA-9062-4A55-AE2C-D46B185F578DQ33765738-860A1F6B-8E02-430A-86A7-43056DC07BF9Q33785735-700D4F4E-A849-44F9-94EB-9B4286EEDBEEQ34043097-14633A80-2811-4CD0-A2A9-6660D13C5F9CQ34262561-5AFFD818-1AD8-4AC5-9AF5-FFE456AC0208Q34434750-35B50E95-B207-433E-94C0-00BC2015EB62Q34489972-412ED3D7-1AF4-469E-B2E6-82C6EE759A13Q34895303-AA66ACB8-1129-4958-B574-0D87F5A9D331Q35041117-E1CE2B3F-F2FE-44E2-9E85-4207518EB3C8Q35084293-B851FD97-5CE7-47A4-8754-4814333BEA7EQ35102141-16E8ED4E-B65D-46FE-B114-5ECAB133CF85Q35122583-41F02E28-193F-439B-9141-3EC3A1429C4CQ35135936-96624801-206E-40BD-AE10-41039F8281E9Q35184223-0426B11E-53BF-4B01-9892-C724499C59D0Q35219001-7B98003C-8416-49B7-8BF0-4A47641CBC31Q35291353-6972FAF3-295C-497C-80BF-739F73EBC3E2Q35804717-B2D08B7F-D4FB-41D6-9409-C26849A8DBC9Q36027314-84870E2B-3B5F-4788-AA60-F8A65B20DCCBQ36183846-38C71FC7-5273-460B-8636-064EACD821B5Q36304070-015A7BAE-8C37-439D-B97E-407A9F0800BBQ36517235-407F3414-A0C0-4FCB-91DA-0CF45FCE4330
P2860
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@ast
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@en
type
label
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@ast
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@en
prefLabel
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@ast
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@en
P2093
P50
P356
P1476
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
@en
P2093
Alberto Martini
Alexei Grom
Berit Flato
Bo Magnusson
Carine Wouters
Daniel J Lovell
Dennis Kim
Flavio Sztajnbok
Gerd Horneff
Hermine I Brunner
P304
P356
10.1056/NEJMOA1205099
P407
P577
2012-12-01T00:00:00Z